News & events Upcoming events Dec 13, 2023 - Dec 14, 2023 USPALZ 2023 (Congrès National des Unités de Soins, d'Évaluation et de Prise en Charge Alzheimer) Issy-les-Moulineaux (Paris), France More info and meet us there Feb 5, 2024 - Feb 8, 2024 Medlab Middle East 2024 Dubai, United Arab Emirates More info and meet us there Mar 5, 2024 - Mar 9, 2024 AD/PD 2024 - International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders Lisbon, Portugal More info and meet us there See all upcoming events Latest news Nov 30, 2023 Fujirebio and Sysmex expand CDMO partnership into the field of neurodegenerative diseases under their immunoassay collaboration Fujirebio Holdings, Inc. (President and CEO: Goki Ishikawa) and Sysmex Corporation (President: Kaoru Asano) today announced that they have... Read more Oct 10, 2023 Fujirebio and Sysmex enter into basic agreement on business collaboration in the field of Immunoassay Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru... Read more Aug 8, 2023 Fujirebio joins the Global Health Innovative Technology (GHIT) Fund H.U. Group Holding Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (President and CEO: Goki Ishikawa; Head Office: Minato-ku... Read more Jul 17, 2023 Beckman Coulter and Fujirebio partner to bolster access to patient-friendly, blood-based Alzheimer’s disease test therapeutics Collaboration builds upon Fujirebio expertise in neurodegenerative disease assays and Beckman Coulter’s high sensitivity, high throughput... Read more Mar 31, 2023 Fujirebio further extends its fully automated blood-based biomarker portfolio with the fully automated Lumipulse® G ApoE4 and Lumipulse® G Pan-ApoE assays for Research Use Only H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G ApoE4 and Lumipulse G... Read more Mar 28, 2023 Fujirebio expands its assay menu in the field of neurodegenerative diseases with the launch of the fully automated Lumipulse® G NfL CSF and Lumipulse® G NfL Blood tests Gent, Belgium, Malvern PA, USA, and Tokyo, Japan, March 28, 2023 – H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today... Read more Load More
Dec 13, 2023 - Dec 14, 2023 USPALZ 2023 (Congrès National des Unités de Soins, d'Évaluation et de Prise en Charge Alzheimer) Issy-les-Moulineaux (Paris), France More info and meet us there
Feb 5, 2024 - Feb 8, 2024 Medlab Middle East 2024 Dubai, United Arab Emirates More info and meet us there
Mar 5, 2024 - Mar 9, 2024 AD/PD 2024 - International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders Lisbon, Portugal More info and meet us there
Nov 30, 2023 Fujirebio and Sysmex expand CDMO partnership into the field of neurodegenerative diseases under their immunoassay collaboration Fujirebio Holdings, Inc. (President and CEO: Goki Ishikawa) and Sysmex Corporation (President: Kaoru Asano) today announced that they have... Read more
Oct 10, 2023 Fujirebio and Sysmex enter into basic agreement on business collaboration in the field of Immunoassay Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru... Read more
Aug 8, 2023 Fujirebio joins the Global Health Innovative Technology (GHIT) Fund H.U. Group Holding Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (President and CEO: Goki Ishikawa; Head Office: Minato-ku... Read more
Jul 17, 2023 Beckman Coulter and Fujirebio partner to bolster access to patient-friendly, blood-based Alzheimer’s disease test therapeutics Collaboration builds upon Fujirebio expertise in neurodegenerative disease assays and Beckman Coulter’s high sensitivity, high throughput... Read more
Mar 31, 2023 Fujirebio further extends its fully automated blood-based biomarker portfolio with the fully automated Lumipulse® G ApoE4 and Lumipulse® G Pan-ApoE assays for Research Use Only H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G ApoE4 and Lumipulse G... Read more
Mar 28, 2023 Fujirebio expands its assay menu in the field of neurodegenerative diseases with the launch of the fully automated Lumipulse® G NfL CSF and Lumipulse® G NfL Blood tests Gent, Belgium, Malvern PA, USA, and Tokyo, Japan, March 28, 2023 – H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today... Read more
